This seems to be the heart of the article:
Quote:
Avastin's so-called "accelerated approval" was based on the condition that later studies would show a survival benefit.
But in briefing documents posted online,FDA reviewers said two follow-up studies recently submitted by Roche failed to show that Avastin significantly extended lives compared to chemotherapy alone.
Additionally, the FDA said that in follow-up studies the drug did not slow tumor growth to the same degree as in earlier studies.
Patients taking Avastin showed significantly more side effects, including high blood pressure, fatigue and abnormal white blood cell levels.
|
There has been some suggestion that it might be a drug that should be continued after progression to avoid rebound, kind of as a base to layer other chemos on top of. More frequent dosing could be beneficial as well.
Might do better with an Hif1 inhibitor.
Been tracking angiogenesis here:
http://her2support.org/vbulletin/sho...218#post221218